Novo Nordisk To Start Phase 3 Trial Of Amycretin For Weight Loss In Early 2026
13/6 03:20
(RTTNews) - Novo Nordisk (NVO) announced that it will advance subcutaneous and oral amycretin into phase 3 development in weight management based on completed clinical studies. This decision was based on positive results from earlier studies and feedback from health authorities....